ABSTRACT

Purpose: To formulate a novel drug delivery system for ophthalmic use for the treatment of bacterial conjunctivitis. To enhance solubility of poorly water-soluble drug loteprednol etabonate and formulate ocular inserts of fluoroquinolone moxifloxacin with loteprednol etabonate and evaluate its potential as a sustained ocular delivery system for the treatment of bacterial conjunctivitis. Methods: Moxifloxacin and loteprednol etabonate compatibility individually and with the polymer and excipients were checked based on preformulation studies. Three different combinations of moxifloxacin and loteprednol etabonate incorporated with carbopol 974, 980, 981, PEG 400 and glycerine were formulated by solvent cast method and evaluated for clarity, smoothness, surface pH, drug content, and in- vitro drug release study. Results: Clarity, smoothness, surface pH, drug content, and in-vitro drug release study were the various parameters evaluated on the formulated ocusert of moxifloxacin and loteprednol etabonate. Conclusion: Formula MLE 81(Moxifloxacin with Loteprednol Etabonate and Carbopol 981) fulfilled the needs of all organoleptic parameters and also the invitro release study. Based on in vitro correlation stabilitystudies, it was concluded this ocular insert is a promising ocular drug delivery system for pharmaceutical researchers. Keywords: Moxifloxacin, Loteprednol Etabonate, Carbopol 974, 980, 981, Ocular inserts and Beta- cyclodextrin complex
Publication date: 01/09/2024

https://ijbpas.com/pdf/2024/September/MS_IJBPAS_2024_8334.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.9.8334